Clinical Trials Logo

Filter by:
NCT ID: NCT05481385 Enrolling by invitation - Pharmacokinetics Clinical Trials

Bioequivalence Study of Ezetimibe Tablets Under Fed Conditions in Healthy Subjects

Start date: July 15, 2022
Phase: Phase 1
Study type: Interventional

The fed bioequivalence test adopts the experimental design of single center, single oral administration, random, open, two sequence, two cycle crossover and self-control.

NCT ID: NCT05475782 Enrolling by invitation - Clinical trials for Pancreatic Duct Stone

Spyglass-guided Lithotripsy Versus ESWL for Pancreatic Duct Stones

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Overall stone clearance with endoscopic retrograde cholangiopancreatography (ERCP) for pancreatic duct stones is a amjor problem, especially bigger size stones. After ERCP failure, surgery was the only option but patients not suitable for surgery were treated through stenting. But had to undergo multiple ERCPs and show lower success rate. Recently, SpyGlass and extracorporeal shock wave lithotripsy (ESWL) have been applied for the treatment of huge stones. The present study aims to compare the efficacy and safety outcomes of SpyGlass-guided lithotripsy and ESWL procedures for the removal of pancreatic duct stones.

NCT ID: NCT05472870 Enrolling by invitation - Clinical trials for Autism Spectrum Disorder

Efficacy and Mechanism of rTMS in Children With ASD: an Open-label Clinical Trial(Ⅱ)

Start date: July 12, 2022
Phase: N/A
Study type: Interventional

This study is a open-label clinical trial involving over 30 children aged ≥4 years with autism spectrum disorder. During the study, subjects received repeated transcranial magnetic stimulation (rTMS) intervention at the left primary motor cortex (M1) 10 times per day for 5 days. From the beginning of intervention to the end of 4 weeks after the completion of intervention, the subjects's clinical symptomatology, cognitive psychology, neuroimaging, and adverse events will be followed up. Based on results from a recent unpublished pilot data, the investigators propose that cTBS treatment will induce a significant improvement in verbal/social communication performance in ASD children.

NCT ID: NCT05448222 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies

Start date: July 1, 2022
Phase:
Study type: Observational

Sarcopenia is associated with the prognosis of HCC and cholangiocarcinoma. But there has been rare study focusing on the effect of sarcopenia on the prognosis of HCC treated with systemic therapy, such as interventional therapy, targeted therapy, chemotherapy and immunotherapy and so on.

NCT ID: NCT05447585 Enrolling by invitation - Clinical trials for Calcification of Coronary Artery

Coronary Atherectomy System in Patients With Coronary Calcification (CORECT)

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This is a prospective and multicenter clinical investigation aiming to evaluate the safety and effectiveness of coronary atherectomy system for the treatment of patients with coronary calcification.

NCT ID: NCT05443230 Enrolling by invitation - Sarcopenia Clinical Trials

Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment

Start date: June 1, 2022
Phase:
Study type: Observational

Sarcopenia is associated with the prognosis of HCC and cholangiocarcinoma. But there has been rare study focusing on the effect of sarcopenia on the prognosis of HCC treated with lenvatinib and anti-PD1.

NCT ID: NCT05443217 Enrolling by invitation - Liver Cancer Clinical Trials

Relationship Between Microbiota and Prognosis of Hepatocellular Carcinoma(HCC) After Systemic Treatments

Start date: June 1, 2022
Phase:
Study type: Observational

By tracking the short-term and long-term results of HCC patients treated with systemic therapies,the difference of microbiota between responded patients and non-responded patients was analyzed, and the correlation between gut and oral microbiota and short-term and long-term results was explored, so as to improve people's awareness of microbiota and pay attention to its prevention and treatment.

NCT ID: NCT05441566 Enrolling by invitation - NSCLC MRD ctDNA Clinical Trials

Significance of MRD After Surgery in Driver Gene-positive and Driver Gene-negative Stage IB-IIA NSCLC

Start date: June 1, 2022
Phase:
Study type: Observational

1. It has been controversial whether adjuvant therapy should be done for patients with stage IB NSCLC after surgery in clinical practice, and identifying patients with high-risk recurrence and those who can benefit from adjuvant therapy is an important clinical problem to be solved. Therefore, the first key scientific issue to be solved in this topic is to analyze the correlation between MRD detection results and both recurrence and adjuvant therapy efficacy by focusing on the stage IB-IIA postoperative NSCLC patient population. To provide clinical data to aid clinical screening of NSCLC patients at high risk of recurrence after surgery in stage IB-IIA. 2, if the detection of MRD has important clinical value such as accurately identifying the population at high risk of recurrence of stage IB-IIA NSCLC, the differences in MRD, etc. between driver gene-positive and -negative patients require further comparative analysis. The second key scientific issue to be solved in this topic is: the different role of MRD in driver gene-positive and driver gene-negative patients: comparison of positive rates, analysis of prognostic differences; and providing clinical data for elucidating the differences between driver gene-positive and -negative patients in MRD evaluation of lung cancer. 3. If MRD is different between NSCLC patients with positive and negative driver genes in stage IB-IIA, is there a difference in the biological behavior of the tumors themselves between these two types of patients? Is there a difference in the ability of the tumor tissue itself to shed tumor cells to be released into the blood? The third scientific question to be addressed in this project is to explore the difference in the ability of patients with stage IB-IIA NSCLC to release ctDNA from their tumors by analyzing the correlation between detailed clinicopathological data and MRD. To provide a scientific basis for exploring the differences in tumor biological behavior between NSCLC driver gene positive and negative.

NCT ID: NCT05434403 Enrolling by invitation - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Transauricular Vagus Nerve Stimulation in the Treatment of Chemotherapy-induced Peripheral Neuropathy

Start date: June 2, 2022
Phase: N/A
Study type: Interventional

Chemotherapy induced peripheral neuropathy is common in tumor patients receiving chemotherapy. Nowaday, CIPN is mainly treated with drugs, but the therapeutic effect is not satisfactory. Previous studies have found that inflammatory immune mechanism plays an important role in neuropathic pain. Vagus nerve stimulation can not only relieve pain by regulating the autonomic nervous system, but also participate in the immune response. Investigators hope that the treatment by vagus nerve electrical stimulation through ear skin can improve the pain and neurotoxicity scores of CIPN patient.If it is proved that vagus nerve stimulation can effectively treat CIPN, it will become a simple and safe non-drug treatment which has good application prospects.

NCT ID: NCT05433363 Enrolling by invitation - Alzheimer Disease Clinical Trials

Renji Alzheimer's Disease Neuroimaging Cohort Study

Start date: February 14, 2022
Phase:
Study type: Observational

This study focuses on the population of Alzheimer disease (AD). Based on Aβ(A)-Tau(T)-Vascular(V)-Neurodegeneration(N) (ATV(N))-AD evaluation system of NIA-AA Association, it can accurately diagnose and predict early AD. Positron emission tomography (PET) - magnetic resonance (MR) was used to perform Aβ、Tau molecular imaging, representing A and T in the system respectively; The quantitative detection of glucose metabolism in the brain by fluorodeoxyglucose PET (FDG-PET) can reflect the degree of neuronal damage (N); In addition, PET-MR can be used to synchronously evaluate the patients' vascular comorbidity (SVD load score) (V). Through the preliminary construction of this system, to clarify the central deposition pattern of Aβ、tau protein and the characteristics of FDG metabolism; To clarify the correlation between PET-MR imaging indexes and the progression of early cognitive impairment in AD, and to clarify the role of degeneration and vascular factors in the occurrence and development of AD; To provide a preliminary basis for the subsequent establishment of a molecular imaging model for the prognosis of early AD.